EverSource Wealth Advisors’s Definium Therapeutics DFTX Stock Holding History

EverSource Wealth Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.2K	Sell	281 -14	-5%	-$346	﹤0.01%	2732
2026 Q1	$5.58K	Buy	295 +41	+16%	+$696	﹤0.01%	3219
2025 Q4	$3.4K	Buy	254 +150	+144%	+$1.86K	﹤0.01%	3283
2025 Q3	$1.23K	Buy	104 +14	+16%	+$131	﹤0.01%	3697
2025 Q2	$584	Buy	90 +34	+61%	+$224	﹤0.01%	3865
2025 Q1	$328	Buy	56 +43	+331%	+$308	﹤0.01%	3582
2024 Q4	$90	Buy	+13	New	+$89	﹤0.01%	3567

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EverSource Wealth Advisors's DFTX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Definium Therapeutics (DFTX) stake by 4.7% in Q2 2026, selling an estimated $346 and leaving 281 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2732.

EverSource Wealth Advisors first reported a position in DFTX in Q4 2024 and has held it in 7 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

EverSource Wealth Advisors held 281 shares of Definium Therapeutics worth $13.2K as of Q2 2026.
EverSource Wealth Advisors sold 14 Definium Therapeutics shares in Q2 2026, an estimated $346.
Definium Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2732 holding.
EverSource Wealth Advisors first reported a position in Definium Therapeutics in Q4 2024 and has held it in 7 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.